中国首批科兴疫苗抵达印尼 即将全民接种
香港01 12-06 17:42
中国科兴生物研製的新型冠状病毒(COVID-19)疫苗,首批约120万剂已在12月6日运抵印尼。印尼预料将利用疫苗开展全民接种计划。
![]()
图为12月6日,中国科兴製药首批新冠疫苗抵达雅加达机场。政府将计划开展接种计划。(Reuters)
科兴生物的新冠疫苗在6日晚运抵雅加达机场。总统佐科维多多(Joko Widodo)表示,第二批180万剂的疫苗将于1月初付运,而科兴生物亦会在12月及1月向印尼提供足以製造4500万剂疫苗的原材料。
佐科维多多表示,政府已准备就绪,将在一切安排妥当后陆续安排接种,相信疫苗有助控制疫情。疫苗目前仍需要待当地部门批出认可,才会正式使用。
印尼与科兴生物合作,自8月起在国内进行疫苗第三阶段临床测试,有1,600多名志愿者参加。
印尼近日新冠疫情恶化,至12月6日新增确诊逾6,000人,累计逾57万人确诊,是东南亚国家中疫情最严重的地方。
A Chinese Covid-19 Vaccine Has Proved Effective, Its Maker Says
Sinopharm, a state-controlled company, said its candidate had a 79 percent efficacy rate in interim late-stage trials. But the announcement left crucial questions unanswered. Sinopharm’s announcement, only a few sentences long, provided no breakdown of results and left many questions unanswered, adding to a lack of clarity that has dogged China’s coronavirus vaccine development for months.
![]()
China Approves Covid-19 Vaccine as It Moves to Inoculate Millions (Published 2020)
Sinopharm, a state-controlled company, said its candidate had a 79 percent efficacy rate in interim late-stage trials. But crucial questions remained unanswered.www.nytimes.com